Biogen to Highlight Breadth of Alzheimer's Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for DiranersenGlobeNewsWire • 06/29/26
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyoutReuters • 06/26/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIBPRNewsWire • 06/25/26
Biogen to Strengthen Immunology Pipeline With $1B RayThera BuyoutZacks Investment Research • 06/18/26
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 06/11/26
Congresswoman Who Bought No Stocks In 2025 Is Back With More 2026 Trades: Here's The Shopping ListBenzinga • 06/10/26
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough TagZacks Investment Research • 06/05/26
Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular AtrophyGlobeNewsWire • 06/04/26
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus ErythematosusGlobeNewsWire • 06/04/26
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant CongressesGlobeNewsWire • 06/03/26
UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus ErythematosusGlobeNewsWire • 06/01/26
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?Zacks Investment Research • 05/29/26
Biogen Inc. (BIIB) Investors with Losses are Urged to Contact The Gross Law Firm to Discuss Their RightsGlobeNewsWire • 05/29/26
Italy's antitrust regulator opens probe into US Biogen over alleged dominant positionReuters • 05/27/26